Trial Profile
A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Oncolytics Biotech
- 06 Nov 2019 Results presented in the Oncolytics Biotech Media Release.
- 06 Nov 2019 Results assessing efficacy and safety of pembrolizumab in combination with pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma, published in the Clinical Cancer Research.
- 04 Jun 2019 Results of the immune analysis in peripheral blood for the prediction of response to pelareorep plus pembrolizumab in PDAC, presented at the 55th Annual Meeting of the American Society of Clinical Oncology